Who holds the patent for keytruda?

Keytruda Patent Holder: Merck & Co. Inc.

Merck & Co. Inc. holds the patent for Keytruda, also known as pembrolizumab [1]. Developed in collaboration with the National Cancer Institute, Keytruda is a monoclonal antibody used to treat various types of cancer, including melanoma, lung cancer, kidney cancer, and others.

The patent for Keytruda is held under the U.S. Food and Drug Administration's (FDA) Orange Book, which provides information on patented and approved pharmaceuticals.

Patent Expiration Timeline:

The patent for Keytruda is set to expire in 2028 in the United States. However, Merck has agreements in place with several generic manufacturers, under which Keytruda will be available as a biosimilar once the patent expires [2].

Why is the Patent Important?

Merck has exclusive marketing rights for Keytruda in the United States until the patent expires. This exclusivity means that other pharmaceutical companies are prohibited from manufacturing or selling generic versions of the drug, giving Merck a competitive advantage in the market.

How Does this Impact Patients?

The patent for Keytruda has given Merck significant pricing power, which has made the drug more expensive for patients and payers. The patent expiration will likely lead to increased competition, potentially resulting in lower prices for Keytruda and its biosimilars.

References:

[1] https://www.drugpatentwatch.com/medicine/pembrolizumab (Merck's Pembrolizumab patent information)

[2] https://www.merck.com/newsroom/news-archive/news.html?year=2022&news_id=14745 (Merck's agreement with generic manufacturers)